medical guideline

Guideline for PET/CT Imaging of Neuroendocrine Neoplasms with 68Ga-DOTA-conjugated Somatostatin Receptor Targeting Peptides

原文:2021年 发布于 Nuclear Medicine Seminars 6卷 第1期 397-405 浏览量:264 原文链接


归属分类: 所属人体系统: 神经内分泌 | 分类: 神经内分泌肿瘤

关键词: Ga-68 DOTA Conjugated Peptide NET PET/CT


Neuroendocrine tumors (NETs) are one of the rare cancers that have been increasing in recent years. The importance of Ga-68 DOTA-Conjugated Peptides Receptor imaging has been reported in many retrospective and prospective studies in the diagnosis and clinical management of NETs. Three different somatostatin analogues labeled Ga-68 are used in clinical practice. The most commonly used Ga-68 DOTA-Conjugated Peptides are DOTA-D-Phe-Tyr3-octreotide (DOTA-TOC), DOTA-1-NaI (3)- octreotide (DOTA-NOC) and DOTA-D-Phe-Tyr3-octreotate (DOTA-TATE) in rutin. Although all these radiopeptides bind to sst-r 2, each has different affinity profiles for other sst-r subtypes. Performed related studies have shown that the compound with the highest affinity for somatostatin receptor 2 (sst-r 2), which is most frequently expressed in NETs, is DOTA-TATE. Ga-68 DOTA-bound somatostatin receptor (sst-r) PET/CT is used in the preoperative staging of NETs, determination of treatment response, restaging, showing somatostatin receptor uptake before peptide receptor radionuclide treatment. This guideline, mainly for nuclear medicine physicians contains recommendations in terms of procedure, reporting and interpretation in order to standardize Ga-68 DOTA conjugated peptid PET/CT imaging in NETs.